CNSP logo

CNS Pharmaceuticals (CNSP) Company Overview

Profile

Full Name:

CNS Pharmaceuticals, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

November 8, 2019

Indexes:

Not included

Description:

CNS Pharmaceuticals is a biotechnology company focused on developing innovative treatments for brain cancer. They aim to improve patient outcomes through advanced therapies, particularly targeting glioblastoma, a challenging type of brain tumor. Their research emphasizes safety and effectiveness in addressing critical medical needs.

Events Calendar

Earnings

Next earnings date:

Apr 1, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Apr 1, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jun 5, 2024

Analyst ratings

Recent major analysts updates

Feb 2, 21 Brookline Capital
Buy
Aug 24, 20 Ladenburg Thalmann
Buy
Dec 4, 19 Benchmark
Speculative Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

CNS Pharmaceuticals to Present at Two Investor Conferences in April
CNS Pharmaceuticals to Present at Two Investor Conferences in April
CNS Pharmaceuticals to Present at Two Investor Conferences in April
CNSP
AccesswireApril 1, 2024

HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at two upcoming investor conferences being held in New York City in April. In addition to the presentations, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the respective conferences.

CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
CNSP
AccesswireSeptember 5, 2023

Live webcast presentation on Wednesday, September 13th at 10:30 AM ET HOUSTON, TX / ACCESSWIRE / September 5, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York, NY on Wednesday, September 13, 2023 at 10:30 AM ET.

CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study
CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study
CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study
CNSP
AccesswireApril 27, 2023

Live moderated video webcast with members of CNS Pharmaceuticals management on Wednesday, May 3rd at 12:00 PM ET HOUSTON, TX / ACCESSWIRE / April 27, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study on Wednesday, May 3, 2023 at 12:00 PM ET. As part of the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President, Clinical Operations of CNS Pharmaceuticals will discuss the progress of its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.

Buying Energy Penny Stocks? 3 Methods to Use
Buying Energy Penny Stocks? 3 Methods to Use
Buying Energy Penny Stocks? 3 Methods to Use
CNSP
PennyStocksApril 16, 2023

Investing in energy penny stocks? Here's some top tips The post Buying Energy Penny Stocks?

CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event
CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event
CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event
CNSP
PRNewsWireMarch 29, 2023

Live moderated video webcast with members of CNS Pharmacetucals management and Key Opinion Leader, Professor Michael Weller, MD, on Tuesday, April 4 th at 3:00 PM ET HOUSTON , March 29, 2023 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the Virtual Investor GBM Spotlight Event on Tuesday, April 4, 2023 at 3:00 PM ET. As part of the event, John Climaco, Chief Executive Officer of CNS Pharmaceuticals will be joined by Key Opinion Leader Professor Michael Weller, MD, to discuss GBM, the unmet need and the work CNS Pharmaceuticals is doing to advance Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.

FAQ

  • What is the ticker symbol for CNS Pharmaceuticals?
  • Does CNS Pharmaceuticals pay dividends?
  • What sector is CNS Pharmaceuticals in?
  • What industry is CNS Pharmaceuticals in?
  • What country is CNS Pharmaceuticals based in?
  • When did CNS Pharmaceuticals go public?
  • Is CNS Pharmaceuticals in the S&P 500?
  • Is CNS Pharmaceuticals in the NASDAQ 100?
  • Is CNS Pharmaceuticals in the Dow Jones?
  • When was CNS Pharmaceuticals's last earnings report?
  • When does CNS Pharmaceuticals report earnings?
  • Should I buy CNS Pharmaceuticals stock now?

What is the ticker symbol for CNS Pharmaceuticals?

The ticker symbol for CNS Pharmaceuticals is NASDAQ:CNSP

Does CNS Pharmaceuticals pay dividends?

No, CNS Pharmaceuticals does not pay dividends

What sector is CNS Pharmaceuticals in?

CNS Pharmaceuticals is in the Healthcare sector

What industry is CNS Pharmaceuticals in?

CNS Pharmaceuticals is in the Biotechnology industry

What country is CNS Pharmaceuticals based in?

CNS Pharmaceuticals is headquartered in United States

When did CNS Pharmaceuticals go public?

CNS Pharmaceuticals's initial public offering (IPO) was on November 8, 2019

Is CNS Pharmaceuticals in the S&P 500?

No, CNS Pharmaceuticals is not included in the S&P 500 index

Is CNS Pharmaceuticals in the NASDAQ 100?

No, CNS Pharmaceuticals is not included in the NASDAQ 100 index

Is CNS Pharmaceuticals in the Dow Jones?

No, CNS Pharmaceuticals is not included in the Dow Jones index

When was CNS Pharmaceuticals's last earnings report?

CNS Pharmaceuticals's most recent earnings report was on Nov 14, 2024

When does CNS Pharmaceuticals report earnings?

The next expected earnings date for CNS Pharmaceuticals is Apr 1, 2025

Should I buy CNS Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions